An observational study in Aortic Valve Disease, sponsored by Baylor Research Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Baylor Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Aortic Valve Disease with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Aortic Valve Disease · United States.
Among the 47 studies in Aortic Valve Disease with a site in United States, this one is the 6th largest by planned enrollment of the 16 observational ones that give a count, is one of 3 that started in 2023, is one of 16 observational ones, reaches primary completion later than 11 of the 22 other live ones, and was the 40th registered.
235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.
Browse Aortic Valve Disease studies →12 of the 47 studies in Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:
EmStop Inc · Sites in United States
Ages 22+
Columbia University · Sites in United States
Ages 18+
EnCompass Technologies, Inc. · Sites in United States, Australia
Ages 21–90
University of Colorado, Denver · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 2 · Phase 4 2
First in 1998; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 225 is above the median of 200 across 107 observational studies indexed under Aortic Valve Disease.
Median enrollment 190 across the 31 interventional studies, 109 across the 16 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 47 have an industry lead sponsor. The 10 most frequent:
Baylor Research Institute is the lead sponsor of 224 studies on the registry; 48 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 9 (39%) have results posted.
Baylor Research Institute has 2 studies filed under Aortic Valve Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Aortic Valve Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06506903Medtronic Cardiac SurgeryAvalus Ultra Post-Approval Study (PAS) | 2026-11 |
| NCT06689839EnCompass Technologies, Inc.Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | 2026-12 |
| NCT02744677Edwards LifesciencesCOMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | 2026-12 |
| NCT06352671Baylor Research InstituteProspective Long-Term Outcomes of a Standardized Ross Procedure | 2026-12-01 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 47 studies in Aortic Valve Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This standardized prospective long-term outcome analysis will help reaffirm these findings via a multicenter patient cohort and describe the best practices/techniques for stabilization of the autograft and right ventricular outflow tract reconstruction.
The optimal approach for aortic valve replacement in adults with an anticipated life expectancy greater than fifteen years remains unclear. Mechanical and bioprosthetic valves, while often used, have specific downfalls. Mechanical valves require lifelong anticoagulation usage and bioprosthetic tissue valves have a limited lifespan. The Ross procedure (pulmonary autograft replacement) is the only operation which replaces the diseased aortic valve with a living substitute. Concerns over increased surgical risk and potential long-term failure have shown decreased use of this procedure. However, recent publications from expert centers have shown, in the current era the Ross procedure can be reliably performed safely and reproducibly in selected patients. This standardized prospective long-term outcome analysis will help reaffirm these findings via a multicenter patient cohort and describe the best practices/techniques for stabilization of the autograft and right ventricular outflow tract reconstruction.
Eligible patients undergoing the Ross procedure at the four institutions of the NARC will be included in this study. The primary study center will be Baylor Scott and White The Heart Hospital. The other member institutions include: The University of Pennsylvania, The University of Washington, and Northwestern University. The investigators estimate to enroll around 20 subjects per year at each institution. This will total 80 subjects per year. The investigators plan to enroll patients for 10 years during the duration of the study. The investigators plan to follow patients for their lifetime.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Survival of the patient
The primary endpoint of this study will be survival at 1-, 5-, and 10-year intervals.
Time frame: 1 year, 5 year and 10 year
Rate of re-hospitalization
To identify the safety of the Ross procedure measured in percentage
Time frame: 1 year after the procedure
Rate of peri operative morbidity
Will be measured in percentage
Time frame: 1 year after the procedure
Rate of re-operation
Will be measured in percentage
Time frame: 1 year after the procedure
Rate of re-intervention
will be measured in percentage
Time frame: 1 year after the procedure
NYHA status
Will be measured as NYHA class I, II,III, IV
Time frame: 1 year after the procedure
Rate of Patients with Anticoagulant Usage
Rate of Patients with Anticoagulant Usage 1 year after procedure.
Time frame: 1 year after the procedure
Rate of Bleeding Events
Rate of Bleeding Events
Time frame: 1 year after the procedure
Rate of Post Operative Infection
Rate of Post Operative Infection
Time frame: 1 year after the procedure
Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.
Of 47 non-industry observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 147. This study's planned 37 months is below that.
Counting every sponsor, half of 56 studies reached it within 49 months; a quarter within 23 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.